STOCK TITAN

Sonnet BioTherapeutics Holdings Inc - SONN STOCK NEWS

Welcome to our dedicated news page for Sonnet BioTherapeutics Holdings (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet BioTherapeutics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sonnet BioTherapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sonnet BioTherapeutics Holdings's position in the market.

Rhea-AI Summary
Sonnet BioTherapeutics regains compliance with Nasdaq minimum bid price requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. announces a 1-for-22 reverse stock split to increase per share trading price and meet Nasdaq listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
none
-
Rhea-AI Summary
Sonnet BioTherapeutics' IND for SB221 (NCT05756907) has been accepted by the FDA, allowing the Phase 1b/2a clinical trial of SON-1010(IL12-FHAB) in combination with Roche's atezolizumab to begin in the US for the treatment of platinum-resistant ovarian cancer (PROC). The trial aims to establish the maximum tolerated dose (MTD) of SON-1010 and confirm clinical benefit in PROC. Additionally, the study will investigate SON-1010 monotherapy, its combination with atezolizumab, or standard of care (SOC) in a randomized comparison to show proof-of-concept (POC). The addition of US trial sites is expected to accelerate the recruitment rate. SON-1010 is a proprietary version of IL-12 with extended pharmacokinetic properties, and atezolizumab is an approved immune checkpoint inhibitor for cancer treatment. The combination of these two agents presents an opportunity to address the unmet medical need in ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.15%
Tags
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the initiation of a combination study of SON-1010 with Roche's atezolizumab in Australia, the completion of the first SON-1010 Phase 1 study, and early safety data from the SON-080 trial in CIPN. The collaboration with Janssen to evaluate the efficacy of SON-1010, SON-1210, and SON-1410 with certain Janssen cell therapy assets is ongoing. The company also provided financial results for the three months ended June 30, 2023, showing $7.0 million cash on hand and a decrease in research and development expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference on August 7-8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.05%
Tags
-
Rhea-AI Summary
Sonnet BioTherapeutics Holdings, Inc. announced positive data from clinical trials of SON-1010 and SON-1210. SON-1010 showed a prolonged and controlled IFN-γ response and clinical benefit in 36% of patients with advanced solid tumors. SON-1210 was well tolerated in non-human primates. The company also completed a $15.0 million public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
Sonnet BioTherapeutics Holdings Inc

Nasdaq:SONN

SONN Rankings

SONN Stock Data

6.14M
2.71M
9.22%
3.53%
14.73%
Food Service Contractors
Accommodation and Food Services
Link
US
Princeton

About SONN

sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies